Bristol Myers Squibb (CELG-RI) Short term Debt (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Short term Debt data on file, last reported at $2.3 billion in Q1 2026.

• Short term Debt for Q1 2026 came in at $2.3 billion, down 35.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (down 35.06% YoY), and the FY2025 annual result was $2.3 billion, up 10.51% from the prior year.
• Short term Debt advanced to $2.3 billion in Q1 2026 per CELG-RI's latest filing, from $2.3 billion in the prior quarter.
• Over five years, Short term Debt peaked at $7.5 billion in Q1 2022 and troughed at $1.1 billion in Q3 2024.
• A 5-year average of $3.7 billion and a median of $3.5 billion in 2024 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2022 and 2024: Short term Debt surged 323.3% in 2022, then sank 80.28% in 2024.
• A 5-year view of Short term Debt shows it stood at $4.3 billion in 2022, then declined by 26.85% to $3.1 billion in 2023, then sank by 34.4% to $2.0 billion in 2024, then gained by 10.51% to $2.3 billion in 2025, then climbed by 2.08% to $2.3 billion in 2026.
• Business Quant data shows CELG-RI's Short term Debt at $2.3 billion in Q1 2026, $2.3 billion in Q4 2025, and $4.5 billion in Q3 2025.